Vascular Inflammation in Adolescents With Type 1 Diabetes
NCT ID: NCT00933101
Last Updated: 2011-06-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
51 participants
OBSERVATIONAL
2010-01-31
2011-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Vascular Function in Adolescent, Diabetic Children
NCT00348179
Vascular Complications in Children From T1D Diagnosis
NCT05790785
Cardiac Dysfunction in Adolescents With Type 1 Diabetes: Contribution of Daily-life Glucoregulation and Impact on Cardiorespiratory Exercise Capacity
NCT04052919
EMERALD: Effects of Metformin on Cardiovascular Function in Adolescents With Type 1 Diabetes
NCT01808690
Early Detection of Long-term Diabetic Complications in Children and Adolescents With Type 1 Diabetes
NCT05159856
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
HgbA1c <8
Adolescents with HgbA1c \< or equal to 8% for the previous 12 months
No interventions assigned to this group
HgbA1c >10
Adolescents with HgbA1c \> or equal to 10% for previous 12 months
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Tanner stage III-V
* T1DM \> 2 years
* HgbA1c \<8 or \>10 for previous 2 years
Exclusion Criteria
* Family history of premature cardiovascular disease
* Hypertension defined as subjects with blood pressure greater than the 90th percentile for age
* Anemia defined as Hgb \<11.0 g/dl
* ADHD
* Congenital heart disease
* Pituitary tumor
* Known allergy to ultrasound gel
* Recent head injury
* Chromosomal abnormalities
12 Years
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Children's Mercy Hospital Kansas City
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Department of Endocrinology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ghufran Babar, MD
Role: PRINCIPAL_INVESTIGATOR
Children's Mercy Hospital Kansas City
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Children's Mercy Hospitals and Clinics
Kansas City, Missouri, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
08 12-200E
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.